{"id":"use-of-sulodexide-orally-only","safety":{"commonSideEffects":[{"rate":null,"effect":"Bleeding"},{"rate":null,"effect":"Gastrointestinal disturbance"},{"rate":null,"effect":"Bruising"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Sulodexide is a mixture of fast-moving heparin and dermatan sulfate that works through multiple anticoagulant and antithrombotic mechanisms. It enhances the activity of antithrombin III and heparin cofactor II, reduces platelet aggregation, and improves blood flow properties. The drug is used orally to prevent thrombotic events and improve microcirculation in various vascular conditions.","oneSentence":"Sulodexide is a glycosaminoglycan that enhances fibrinolysis and inhibits thrombosis by modulating coagulation and fibrinolytic pathways.","_ai_confidence":"medium"},"_scrapedAt":"2026-03-27T23:38:04.688Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Chronic venous insufficiency"},{"name":"Diabetic angiopathy"},{"name":"Thrombotic disorders"},{"name":"Microangiopathy"}]},"trialDetails":[{"nctId":"NCT05005052","phase":"PHASE3","title":"Sulodexide in the Treatment of Chronic Primary Venous Disease of the Lower Extremities","status":"UNKNOWN","sponsor":"Value Outcomes Ltd.","startDate":"2021-11-25","conditions":"Chronic Venous Disease, Chronic Insufficiency Venous","enrollment":290},{"nctId":"NCT03370705","phase":"PHASE3","title":"Endothelial Function Evaluation in Patients With PAOD Treated With Sulodexide + Conventional Treatment (CT) Vs CT Alone","status":"UNKNOWN","sponsor":"Alfa Wassermann Tunisia","startDate":"2019-01-31","conditions":"Peripheral Arterial Obstructive Disease","enrollment":156},{"nctId":"NCT01316068","phase":"PHASE4","title":"Effect of Sulodexide on Albuminuria in Chinese Type 2 Diabetic Patients","status":"UNKNOWN","sponsor":"Sun Yat-sen University","startDate":"2011-03","conditions":"Diabetic Nephropathy, Albuminuria","enrollment":80}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":5,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["oral use of sulodexide"],"phase":"marketed","status":"active","brandName":"use of sulodexide orally only","genericName":"use of sulodexide orally only","companyName":"Sun Yat-sen University","companyId":"sun-yat-sen-university","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Sulodexide is a glycosaminoglycan that enhances fibrinolysis and inhibits thrombosis by modulating coagulation and fibrinolytic pathways. Used for Chronic venous insufficiency, Diabetic angiopathy, Thrombotic disorders.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}